Add to Watchlist
View Current for IBRX
View SuperFeed for IBRX
View Charts for IBRX
Add or remove $IBRX from your watchlists:
Hang tight! We're updating your watchlist data.
This might take a minute...
You have not created a stock watchlist. Create one now to track $IBRX!
ImmunityBio, Inc., a clinical-stage biotechnology company, engages in developing therapies and vaccines that complement, harness, and amplify the imm… more
Explore popular threads around $IBRX
There are no threads for this stock
Go to Thread Explorer
Explore recent charts, graphs, and media
There are no charts for this stock
Get the latest breaking news from the community
There is no recent news for this stock
Loading news, hang tight...
Google Search Trends - Past 12 months
Instantly visualize search trends for this specific symbol
Company ProfileImmunityBio, Inc., a clinical-stage biotechnology company, engages in developing therapies and vaccines that complement, harness, and amplify the immune system to defeat cancers and infectious diseases in the United States and Europe. It offers immunotherapy and cell therapy platforms, including antibody cytokine fusion protein N-803, vaccine technologies, toll-Like receptor activating adjuvants, natural killer cells, and damage-associated molecular patterns inducers. The company also develops therapeutic agents, which are in Phase II or III clinical trial for the treatment of liquid and solid tumors, including bladder, pancreatic, and lung cancers, as well as pathogens as SARS-CoV-2 and HIV. It has collaboration agreements with National Cancer Institute and Amyris, Inc.; and license agreements with LadRx Corporation, GlobeImmune, Inc., Access to Advanced Health Institute, 3M Innovative Properties Company, Sanford Health, Shenzhen Beike Biotechnology Co. Ltd., Sorrento Therapeutics, Inc., and Viracta Therapeutics, Inc. The company is based in San Diego, California.
Market Cap Type: Mid